Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Rituximab and prednisone may increase the number of platelets in patients with
immune thrombocytopenic purpura.
PURPOSE: This phase II trial is studying the side effects and how well giving rituximab
together with prednisone works as first-line therapy in treating patients with immune
thrombocytopenic purpura.